Response to the Letter to the Editor by Zambelli et al for In Silico Lung Deposition Profiles of Three Single-Inhaler Triple Therapies in Patients With COPD Using Functional Respiratory Imaging [Response To Letter]

Dave Singh,1 Nicolas Roche,2,3 Libo Wu,4 Hosein Sadafi,5 Jan De Backer,6,7 Navid Monshi Tousi,5 Jonathan Marshall8 1Respiratory Research Group, University of Manchester, Medicines Evaluation Unit, Manchester University National Health Service Foundation Trust, Manchester, UK; 2Department of Respiratory Medicine, Hospital Cochin, APHP Centre, Paris, France; 3Université Paris Cité, Institut Cochin, U1016, Paris, France; 4Product Development Operations, AstraZeneca, Durham, NC, USA; 5Department of Computational Engineering, FLUIDDA NV, Kontich, Belgium; 6FLUIDDA NV, Kontich, Belgium; 7Department of Respiratory Medicine, University of Antwerp, Antwerp, Belgium; 8Global Medical Respiratory, BioPharmaceuticals Medical, AstraZeneca, Cambridge, UKCorrespondence: Jonathan Marshall, Global Medical Respiratory, BioPharmaceuticals Medical, AstraZeneca, 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge, CV2 0AA, UK, Tel +44 (0)20 3749 5000, Email jonathan.marshall1@astrazeneca.com